Sartorius : Conference Call Q1|2021 Presentation PDF | 447.3 KB | April 29, 2021

Conference Call Q1 2021 Results

Joachim Kreuzburg, Rainer Lehmann

Sartorius | Sartorius Stedim Biotech

April 21, 2021

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.

This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

2

Highlights Q1 2021

• Both divisions with 60+ percent top-line growth and substantial margin expansion
• Strong organic growth plus significant impact from corona related businesses and acquisitions
• Q1 top-line and bottom-line growth impacted by low comparative base and temporary effects
• Accelerated capacity expansion on schedule
• Outlook for 2021, raised in mid-March, confirmed

3

Agenda

Sartorius Group

Q1 2021 results | FY 2021 guidance

Sartorius Stedim Biotech Group

Q1 2021 results | FY 2021 guidance

Questions & Answers

4

Strong profitable growth

Sartorius Group	Q1 2020	Q1 2021	in %	in % cc1
in millions of € unless otherwise specified
Sales revenue	509.9	791.1	+55.1	+61.6
Order intake	629.4	1,138.6	+80.9	+89.2
Underlying EBITDA2	137.9	263.5	+91.2
Underlying EBITDA2 margin in %	27.0	33.3	+6.3pp
Underlying EPS3 (ord.) in €	0.83	1.77	+112.4
Underlying EPS3 (pref.) in €	0.84	1.78	+111.1

• Acquisitions contribute about 12pp to sales growth; net effect from pandemic about 20pp / a good 30pp for order intake
• Underlying EBITDA margin driven by economies of scale and underproportionate cost development

1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate

5